富士フイルム：iPSで眼疾患治療：BlueRock に技術供与（動画）：
FUJIFILM:Treatment of eye diseases with iPS:Tech licensed to BlueRock：
FUJIFILM：使用iPS治疗眼部疾病：BlueRock许可的技术
ーバイエル子会社「ブルーロック・セラピューティクス」に技術供与ー
富士フイルム：
5月18日、「 iPS細胞を創薬に利用するためのライセンスのオプション権」を、
「独製薬大手バイエルの米子会社に供与する」と発表した。
ブルーロック・セラピューティクス：
ブルーロックは、「iPS細胞を用いた眼疾患治療法」について、非臨床段階で研究している。
iPS細胞の創薬ライセンス：
一時金は7000万ドル（約76億円）である。
ブルーロックがオプション権を行使した場合、
富士フイルムは、販売ロイヤルティーを10%程度受け取る。
FCDI社とオプシス社：
iPS細胞の培養販売子会社：フジフイルム・セルラー・ダイナミクス（FCDI）、
網膜疾患治療法の開発企業：「オプシス セラピューティクス」、
上記2社が、創薬ライセンスの技術供与元である。
3社の協力体制：
「加齢黄斑変性」や「網膜色素変性症」
「失明につながる目の難病を、iPS細胞を使って治療すること」を目指す。
日本経済新聞
https://www.nikkei.com/article/DGXZQOUC187BA0Y1A510C2000000/
BlueRock Therapeutics, FUJIFILM Cellular Dynamics, and Opsis Therapeutics Enter into a Strategic R&D Alliance to Discover and Develop Cell Therapies for Eye Diseases
Cambridge, Mass., and Madison, Wis. [May 17, 2021]
BlueRock Therapeutics LP, a clinical stage biopharmaceutical company and wholly-owned subsidiary of Bayer AG,
FUJIFILM Cellular Dynamics, Inc. a leading global developer and manufacturer of human induced pluripotent stem (iPS) cell technologies,
Opsis Therapeutics, LLC, a joint venture of FUJIFILM Cellular Dynamics (FCDI)
David Gamm, M.D., Ph.D., co-founder, focusing on developing cell therapies for patients with ocular diseases,
today announced that they have entered into a strategic research and development (R&D) alliance.
As part of the alliance,
the companies will combine their collective expertise to discover and develop off-the-shelf iPS cell therapies for ocular diseases.
Under this agreement,
BlueRock Therapeutics
will have the option to exclusively license from both parties three (3) retinal cell therapy programs focused on
dry age-related macular degeneration (AMD)
inherited retinal diseases (IRDs) containing human retinal pigment epithelial cells
photoreceptor cells, currently in pre-clinical development.
BlueRock Therapeutics, FUJIFILM Cellular Dynamics, and Opsis Therapeutics Enter into a Strategic R&D Alliance to Discover and Develop Cell Therapies for Eye Diseases
Cambridge, Mass., and Madison, Wis. [May 17, 2021]
BlueRock Therapeutics LP, a clinical stage biopharmaceutical company and wholly-owned subsidiary of Bayer AG,
FUJIFILM Cellular Dynamics, Inc. a leading global developer and manufacturer of human induced pluripotent stem (iPS) cell technologies,
Opsis Therapeutics, LLC, a joint venture of FUJIFILM Cellular Dynamics (FCDI)
David Gamm, M.D., Ph.D., co-founder, focusing on developing cell therapies for patients with ocular diseases,
today announced that they have entered into a strategic research and development (R&D) alliance.
As part of the alliance,
the companies will combine their collective expertise to discover and develop off-the-shelf iPS cell therapies for ocular diseases.
Under this agreement,
BlueRock Therapeutics
will have the option to exclusively license from both parties three (3) retinal cell therapy programs focused on
dry age-related macular degeneration (AMD)
inherited retinal diseases (IRDs) containing human retinal pigment epithelial cells
photoreceptor cells, currently in pre-clinical development.
“Millions of patients around the world today are suffering from permanent vision loss as a result of incurable ocular diseases,” states Nick Manusos, Chief Executive Officer, Opsis Therapeutics.
Fujifilm [Japan]